Rigel Pharmaceuticals Analyst Ratings
Rigel Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/02/2023 | 1027.82% | HC Wainwright & Co. | → $15 | Reiterates | Buy → Buy |
| 05/03/2023 | 1027.82% | HC Wainwright & Co. | → $15 | Reiterates | → Buy |
| 04/03/2023 | 50.38% | Piper Sandler | → $2 | Assumes | → Neutral |
| 03/09/2023 | 125.56% | Citigroup | $2 → $3 | Maintains | Buy |
| 03/08/2023 | 1027.82% | HC Wainwright & Co. | → $15 | Reiterates | → Buy |
| 12/02/2022 | — | Citigroup | Upgrades | Neutral → Buy | |
| 11/04/2022 | 125.56% | BMO Capital | $4 → $3 | Maintains | Outperform |
| 08/18/2022 | 1027.82% | HC Wainwright & Co. | $7 → $15 | Maintains | Buy |
| 08/17/2022 | 50.38% | Piper Sandler | $1 → $2 | Maintains | Neutral |
| 06/09/2022 | 125.56% | BMO Capital | $7 → $3 | Maintains | Outperform |
| 06/09/2022 | -6.02% | B. Riley Securities | $4 → $1.25 | Maintains | Neutral |
| 06/09/2022 | -39.85% | Citigroup | $7 → $0.8 | Downgrades | Buy → Neutral |
| 06/08/2022 | 426.32% | HC Wainwright & Co. | $11 → $7 | Maintains | Buy |
| 06/08/2022 | — | Cantor Fitzgerald | Downgrades | Overweight → Neutral | |
| 03/23/2022 | 200.75% | B. Riley Securities | → $4 | Initiates Coverage On | → Neutral |
| 02/18/2021 | 727.07% | HC Wainwright & Co. | $8 → $11 | Maintains | Buy |
| 11/09/2020 | — | JP Morgan | Downgrades | Overweight → Neutral | |
| 08/06/2020 | 501.5% | Citigroup | $7 → $8 | Maintains | Buy |
| 05/27/2020 | 351.13% | JP Morgan | $7 → $6 | Maintains | Overweight |
| 12/09/2019 | 501.5% | BMO Capital | $11 → $8 | Maintains | Outperform |
| 11/15/2019 | 275.94% | Cantor Fitzgerald | $7 → $5 | Maintains | Overweight |
| 09/26/2019 | 426.32% | JP Morgan | → $7 | Assumes | → Overweight |
| 08/27/2018 | 539.1% | Citigroup | → $8.5 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 08/02/2023 | 1027.82% | HC Wainwright & Co. | → 15 美元 | 重申 | 購買 → 購買 |
| 05/03/2023 | 1027.82% | HC Wainwright & Co. | → 15 美元 | 重申 | → 購買 |
| 04/03/2023 | 50.38% | 派珀·桑德勒 | → 2 美元 | 假設 | → 中立 |
| 03/09/2023 | 125.56% | 花旗集團 | 2 美元 → 3 美元 | 維護 | 購買 |
| 03/08/2023 | 1027.82% | HC Wainwright & Co. | → 15 美元 | 重申 | → 購買 |
| 12/02/2022 | — | 花旗集團 | 升級 | 中性 → 買入 | |
| 2022 年 4 月 11 日 | 125.56% | BMO 資本 | 4 美元 → 3 美元 | 維護 | 跑贏大盤 |
| 08/18/2022 | 1027.82% | HC Wainwright & Co. | 7 美元 → 15 美元 | 維護 | 購買 |
| 08/17/2022 | 50.38% | 派珀·桑德勒 | $1 → $2 | 維護 | 中立 |
| 2022 年 9 月 6 日 | 125.56% | BMO 資本 | 7 美元 → 3 美元 | 維護 | 跑贏大盤 |
| 2022 年 9 月 6 日 | -6.02% | B. 萊利證券 | 4 美元 → 1.25 美元 | 維護 | 中立 |
| 2022 年 9 月 6 日 | -39.85% | 花旗集團 | 7 美元 → 0.8 美元 | 降級 | 買入 → 中性 |
| 06/08/2022 | 426.32% | HC Wainwright & Co. | 11 美元 → 7 美元 | 維護 | 購買 |
| 06/08/2022 | — | 坎託·菲茨傑拉德 | 降級 | 超重 → 中性 | |
| 03/23/2022 | 200.75% | B. 萊利證券 | → 4 美元 | 啓動覆蓋開啓 | → 中立 |
| 2021 年 2 月 18 日 | 727.07% | HC Wainwright & Co. | 8 美元 → 11 美元 | 維護 | 購買 |
| 2020 年 9 月 11 日 | — | 摩根大通 | 降級 | 超重 → 中性 | |
| 08/06/2020 | 501.5% | 花旗集團 | 7 美元 → 8 美元 | 維護 | 購買 |
| 05/27/2020 | 351.13% | 摩根大通 | 7 美元 → 6 美元 | 維護 | 超重 |
| 12/09/2019 | 501.5% | BMO 資本 | 11 美元 → 8 美元 | 維護 | 跑贏大盤 |
| 11/15/2019 | 275.94% | 坎託·菲茨傑拉德 | 7 美元 → 5 美元 | 維護 | 超重 |
| 2019 年 9 月 26 日 | 426.32% | 摩根大通 | → 7 美元 | 假設 | → 超重 |
| 08/27/2018 | 539.1% | 花旗集團 | → 8.5 美元 | 啓動覆蓋開啓 | → 購買 |
What is the target price for Rigel Pharmaceuticals (RIGL)?
銳佳製藥（RIGL）的目標價格是多少？
The latest price target for Rigel Pharmaceuticals (NASDAQ: RIGL) was reported by HC Wainwright & Co. on August 2, 2023. The analyst firm set a price target for $15.00 expecting RIGL to rise to within 12 months (a possible 1027.82% upside). 9 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 於2023年8月2日公佈了銳佳製藥（納斯達克股票代碼：RIGL）的最新目標股價。這家分析公司將目標股價定爲15.00美元，預計RIGL將在12個月內升至15.00美元（可能上漲1027.82％）。去年有9家分析公司公佈了評級。
What is the most recent analyst rating for Rigel Pharmaceuticals (RIGL)?
銳佳製藥（RIGL）的最新分析師評級是多少？
The latest analyst rating for Rigel Pharmaceuticals (NASDAQ: RIGL) was provided by HC Wainwright & Co., and Rigel Pharmaceuticals reiterated their buy rating.
銳佳製藥（納斯達克股票代碼：RIGL）的最新分析師評級由HC Wainwright & Co. 提供，銳佳製藥重申了他們的買入評級。
When is the next analyst rating going to be posted or updated for Rigel Pharmaceuticals (RIGL)?
銳佳藥業（RIGL）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Rigel Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Rigel Pharmaceuticals was filed on August 2, 2023 so you should expect the next rating to be made available sometime around August 2, 2024.
分析師在進行了廣泛的研究（包括瀏覽公開財務報表、與銳佳製藥的高管和客戶交談以及聽取業績電話會議）後得出股票評級。大多數分析師每三個月進行一次評級，因此每家公司每年應該獲得4個評級。銳佳製藥公司的最後一次評級是在2023年8月2日提交的，因此您應該預計下一個評級將在2024年8月2日左右公佈。
Is the Analyst Rating Rigel Pharmaceuticals (RIGL) correct?
分析師對銳佳藥業（RIGL）的評級是否正確？
While ratings are subjective and will change, the latest Rigel Pharmaceuticals (RIGL) rating was a reiterated with a price target of $0.00 to $15.00. The current price Rigel Pharmaceuticals (RIGL) is trading at is $1.33, which is within the analyst's predicted range.
儘管評級是主觀的，將會發生變化，但最新的銳佳藥業（RIGL）評級得到了重申，目標股價爲0.00美元至15.00美元。銳佳製藥（RIGL）目前的交易價格爲1.33美元，在分析師的預測區間內。